Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $11.97 (market cap $1.39B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 5.4× YieldMax NVDA Option Income Strategy ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 44 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NVDY | SYRE | |
|---|---|---|
Market Cap | $1.39B | $7.52B |
Volume | 1,855,603 | 1,441,031 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $108.92 |
52-Week Low | $11.58 | $22.18 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.54, up 0.88% on the day. The technical outlook is bearish, with moving averages signaling strong selling pressure, though oscillators are neutral. The fund generates weekly dividends but faces structural limitations on upside participation. Recent news highlights concerns over net asset value erosion despite high distribution yields.
The outlook is cautious; while NVDY offers high income, its strategy caps gains during NVIDIA rallies and may underperform in low-volatility environments. Key risks include NAV decay and reduced option income potential. Investors seeking pure NVIDIA exposure may find direct ownership more attractive for long-term growth.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
